A Phase 2 interventional study of TrenibotulinumtoxinE and OnabotulinumtoxinA and Placebo in Upper Facial Lines and Glabellar Lines, sponsored by AbbVie. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines. The study has two parts; Part 1 evaluates treatment for glabellar lines.
AbbVie is the lead sponsor of 967 studies on the registry; 132 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 214 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA
Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA
Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA
Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA
Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA
Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA
Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA
Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.
Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA
Participants will receive a single treatment of onabotulinumtoxinA.
Drug: OnabotulinumtoxinA
Participants will receive a single treatment of placebo.
Drug: Placebo
Injection
Injection
Injection
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Day 150
Percentage of Participants Achieving None or Mild on the Investigator-Assessed Allergan Glabellar Lines Severity Scale (AGLSS)
Achievement of None or Mild on the investigator-assessed AGLSS. The AGLSS is a validated 4-point scale (0=None through 3=Severe) used to assess glabellar line severity. A response of None or Mild indicates improvement in glabellar line severity.
Time frame: Day 7
Percentage of Participants Achieving None or Mild on the Subject-Assessed AGLSS
Achievement of None or Mild on the subject-assessed AGLSS. The AGLSS is a validated 4-point scale (0=None through 3=Severe) used to assess glabellar line severity. A response of None or Mild indicates improvement in glabellar line severity.
Time frame: Day 7
Duration Area Under the Curve (AUC) for Time-Averaged Response Based on Achievement of None or Mild on the Investigator-Assessed AGLSS
Duration AUC (area under the curve) for time-averaged response based on achievement of None or Mild on the investigator-assessed AGLSS. The AGLSS is a validated 4-point scale (0=None through 3=Severe). This endpoint measures the duration of treatment effect over time.
Time frame: Up to Day 150
Onset Area Under the Curve (AUC) for Time-Averaged Response Based on Achievement of None or Mild on the Investigator-Assessed AGLSS
Onset AUC (area under the curve) for time-averaged response based on achievement of None or Mild on the investigator-assessed AGLSS. The AGLSS is a validated 4-point scale (0=None through 3=Severe). This endpoint measures the rapidity of onset of treatment effect.
Time frame: Up to to Day 7
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jun 2028, 20 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.